Penicillin Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Penicillin Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Penicillin Drug Market studied is expected to grow with an estimated CAGR of 5.2%, over the forecast period (2022 - 2027).

The COVID-19 outbreak has had a significant impact on the market. As employment closures have curtailed import and export activities, there has been a considerable influence on the market, resulting in shortages and unavailability of antibiotic drugs and supplies across healthcare facilities. The initial phase of the outbreak had a significant influence on the market for antibiotic drugs due to the temporary shutdown of production facilities, export restrictions, increased demand for the COVID-19 medication, disruptions in the supply of goods, and interruptions in services for the treatment. For instance, according to an article published by the Elsevier Public Health Emergency Collection, in June 2021, titled “Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study”, it has been observed that bacterial ventilator-associated pneumonia (VAP) affects 10% to 33% of patients who require mechanical ventilation. In addition, as per the same source, 13.5%–44% of COVID-19 patients, who were referred to the intensive care unit (ICU), were found to have bacterial superinfections, with a case fatality rate of 50–100%. Thus, the increasing bacterial infection among hospitalized patients was found to increase the demand for antibiotics which is further expected to increase the demand for penicillin, which is anticipated to have a significant impact on the market growth.

Certain factors that are propelling the market growth are the increasing burden of infectious diseases, growing research and development activities in the pharmaceutical industry, and rising demand and development of generic drugs.

The rising prevalence of bacterial infections such as pneumonia, respiratory tract infections, scarlet fever, and ear, skin, gum, mouth, throat infections, and syphilis coupled with the need for effective and newer antibiotics, is driving the demand for advanced antibiotics. For instance, according to the data published by the Government of the United Kingdom in April 2022, it has been observed that 3,488 cases of scarlet fever were reported in England between October 2021 to March 2022. Additionally, according to the statistics published by the Minnesota Department of Health, in June 2022, the number of congenital syphilis (CS), increased by 115%, up to 15 cases, in Minnesota, 2021. In addition, as per the same source, there was a 33% increase in syphilis cases from 2020 to 1,457 cases recorded in 2021, which represented the largest percentage increase. Thus, the rising burden of infectious diseases among the population is increasing the demand for effective treatment options which is expected to increase the demand for antibiotics, which in turn is anticipated to increase the demand for penicillin, thereby fuelling the market growth.

Furthermore, according to data published by the United Nations Children's Fund (UNICEF), in August 2022, more than 1,400 cases of pneumonia per 100,000 are reported every year, globally. In addition to the above source, the highest incidence of pneumonia occurs in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Similarly, according to the data published by the World Health Organization, in September 2020, titled “Global report on the epidemiology and burden of sepsis”, it has been observed that sepsis has affected 49 million people and was responsible for almost 11 million possibly preventable deaths globally, in 2020. Thus, the rising burden of pneumonia among the population is expected to increase the demand for antibiotics for treatment, thus increasing the market growth.

However, the increasing resistance to anti-microbials, rising discovery, fierce competition with a new class of diverse antibacterial, and stringent regulatory frameworks are likely to restrain the market growth over the forecast period.

Key Market TrendsBroad Spectrum Segment Expects to Register a High CAGR in the Penicillin Drug Market During the Forecast Period

The Broad-Spectrum Penicillin segment is anticipated to hold the major share of revenue in the Spectrum of Activity segment over the forecast period owing to the factors such as the rising burden of infectious diseases, and emerging new antibiotics drugs. Broad-Spectrum Penicillin is antibiotic that act on the two major bacterial groups, Gram-positive and Gram-negative, and also acts against a wide range of disease-causing bacteria.

The increasing incidence of infectious diseases is anticipated to drive the market growth of extended-spectrum penicillin. For instance, according to an article published by StatPearls, in May 2022, titled 'Osteomyelitis", it has been found that 50,000 cases of osteomyelitis are reported each year in the United States. In addition, as per the same source, the incidence of osteomyelitis is higher in men as compared to women and increases with age which is due to the increasing prevalence of comorbid factors such as diabetes mellitus and peripheral vascular disease. Thus, the rising osteomyelitis cases among the population are expected to drive the demand for better treatment medications, which is anticipated to drive the market growth over the forecast period. Additionally, according to an article published by Cureus, in June 2021, titled "Reducing Broad-Spectrum Antibiotic Treatment of Simple Group A Streptococcal Infections to Reduce Harm to the Microbiome", it has been observed that amoxicillin and other broad-spectrum antibiotics are commonly used to treat simple Group A streptococcal (GAS) infections. Similarly, according to the Center for Disease Control and Prevention, in May 2022, 133,945 cases of all stages of syphilis, including 41,655 cases of primary and secondary (P&S) syphilis, were reported in the United States in 2020. Thus, the rising burden of bacterial infections is expected to increase the demand for antibiotic treatment, thereby fueling the segment growth.

Furthermore, the rising company's focus on research and development activities to address the need for a new class of antibiotics that are required to treat emerging resistance bacteria and related infections is also contributing to the growth of the market. For instance, in May 2021, Qpex Biopharma dosed the first patient in a Phase 1 study of ORAvance, an ultra-broad-spectrum oral beta-lactamase inhibitor (QPX7728) for use in combination with beta-lactam antibiotics for drug-resistant gram-negative bacterial infections.

Therefore, due to the aforementioned factors, the studied segment is expected to grow significantly over the forecast period.

North America Dominates the Market and Expects to do Same Over the Forecast Period

North America holds the major market share in the Penicillin Drug market and is expected to dominate the overall market throughout the forecast period owing to the factors such as the rising prevalence of infectious diseases and the presence of better healthcare infrastructure, the presence of key market players, and increasing awareness programs. In addition, the rising geriatric and pediatric population in the region who are more prone to develop infectious diseases due to low immunity is expected to contribute to the growth of the market.

For instance, according to the National Foundation for Infectious Diseases, updated in March 2022, pneumococcal pneumonia hospitalizes around 150,000 individuals in the United States each year. Additionally, according to an article by Forest W. Arnold in May 2020, titled “Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes”, an estimated the burden of community-acquired pneumonia (CAP) in the older adult population of the United States found that the incidence of CAP was about 2100 per 100,000 population. The number corresponds to 970,000 older adults in the United States hospitalized per year with CAP. The study reported 30-day mortalities of 14% for ward patients and 33% for ICU patients, thus showing significant differences and high mortality. Similarly, as per an article published by the National Institute of Health in December 2021, titled “Pressure Injury”, the prevalence of pressure injuries to the skin and soft tissues is affecting an estimate of around 1 to 3 million people in the United States each year, which is expected to increase the demand for amoxicillin drug for treating infected pressure ulcers, thereby propelling the market growth in the region.

Moreover, the rising company's focus on research and development activities for developing effective antibiotics for treating various infectious diseases is also contributing to the growth of the market. For instance, in November 2021, USAntibiotics relaunched production of the amoxicillin manufacturing facility. This is to boost the production of Amoxicillin products to meet the nation's demand for essential medications. Also, in July 2020, Sandoz launched Daptomycin for injection 500 mg, a generic version of Cubicin, in the United States, for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria and certain bloodstream infections, including right-sided infective endocarditis.

Thus, owing to aforesaid developments and the increasing burden of infectious diseases in the region, the market is projected to grow over the forecast period.

Competitive Landscape

The Penicillin Drug Market is highly competitive with the presence of several players across the globe. With the increase in research and development activity, many regional players are expected to contribute to the penicillin drug market over the forecast period. Some of the major players in the market are Pfizer, Inc., Novartis AG, Sanofi S.A., Astellas Pharma, Inc., GlaxoSmithKline plc, Merck Co. and Inc., Fujifilm Toyama Chemical Co. Ltd., Sun Pharmaceutical Industries, Lupin Limited, and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.